LakeShore Biopharma (LSB) Institutional Ownership $1.27 +0.04 (+3.25%) As of 11:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for LakeShore Biopharma (NASDAQ:LSB)CurrentInstitutional OwnershipPercentage52.64%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$16.94MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$3.11M Get LSB Insider Trade Alerts Want to know when executives and insiders are buying or selling LakeShore Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data LSB Institutional Buying and Selling by Quarter LakeShore Biopharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025Orbimed Advisors LLC140,428$486K0.0%N/A1.508% 2/14/2025Hhlr Advisors LTD.75,179$259K0.0%-90.0%0.808% 2/13/2025Barclays PLC24,757$86K0.0%-90.0%0.266% 11/19/2024Barclays PLC247,575$169K0.0%N/A2.660% 11/15/2024Barclays PLC247,575$169K0.0%N/A2.660% 11/14/2024Hhlr Advisors LTD.751,790$513K0.0%N/A8.075% 11/13/2024FMR LLC1,165,071$803K0.0%N/A12.514% (Data available from 1/1/2016 forward) LSB Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LSB shares? During the previous two years, the following institutional investors and hedge funds held shares of LakeShore Biopharma shares: FMR LLC ($803K), Orbimed Advisors LLC ($486K), and Hhlr Advisors LTD. ($259K), Barclays PLC ($86K).Learn more on LakeShore Biopharma's institutional investors. What percentage of LakeShore Biopharma's stock is owned by institutional investors? 52.64% of LakeShore Biopharma's stock is owned by institutional investors. Learn more on LSB's institutional investor holdings. Which institutional investors have been buying LakeShore Biopharma's stock? The following institutional investors have purchased LakeShore Biopharma's stock in the last 24 months: FMR LLC ($1.17M), Hhlr Advisors LTD. ($751.79K), Barclays PLC ($495.15K), and Orbimed Advisors LLC ($140.43K). How much institutional buying is happening at LakeShore Biopharma? Institutional investors have bought a total of 2,552,439 shares in the last 24 months. This purchase volume represents approximately $16.94M in transactions. Which of LakeShore Biopharma's major shareholders have been selling company stock? The following institutional investors have sold LakeShore Biopharma stock in the last 24 months: Hhlr Advisors LTD. ($676.61K), and Barclays PLC ($222.82K). How much institutional selling is happening at LakeShore Biopharma? Institutional investors have sold a total of 899,429 shares in the last 24 months. This volume of shares sold represents approximately $3.11M in transactions. Related Companies Pluri Institutional Ownership LAVA Therapeutics Institutional Ownership KALA BIO Institutional Ownership Shattuck Labs Institutional Ownership Promis Neurosciences Institutional Ownership Xilio Therapeutics Institutional Ownership Iterum Therapeutics Institutional Ownership Karyopharm Therapeutics Institutional Ownership Hyperion DeFi Institutional Ownership Synergy CHC Institutional Ownership This page (NASDAQ:LSB) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LakeShore Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share LakeShore Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
